MING YU PHARMA Re-Files HKEX Listing Application; Morgan Stanley, BofA Securities and CITIC Securities Appointed Joint Sponsors
NewTimeSpace News: Ming Yu Pharmaceutical Limited re-submitted its listing application to HKEX on 8 July, with Morgan Stanley, BofA Securities and CITIC Securities acting as joint sponsors. Founded in 2018, it is an oncology-focused biotech company centred on integrative oncology, specialising in antibody-drug conjugates and advanced immunotherapies. Its pipeline comprises 11 independently discovered and developed candidates including two core assets.
NewTimeSpace News: Ming Yu Pharmaceutical Limited re-filed a listing application with The Stock Exchange of Hong Kong Limited on 8 July 2026. Morgan Stanley, BofA Securities and CITIC Securities have been appointed as the joint sponsors.
Founded in 2018, the Company is a biotechnology enterprise focusing on integrative oncology, dedicated to the research and development combining antibody-drug conjugates (ADCs) and advanced immunotherapies. As of the latest practicable date, its product pipeline covers 11 candidate products, all independently discovered and developed.
Its core asset MHB036C is an ADC candidate for solid tumours, mainly indicated for first-line and subsequent-line treatment of non-small cell lung cancer and breast cancer. MHB018A is an antibody candidate developed for thyroid eye disease, with active thyroid eye disease as its primary indication.
The Company has built a robust clinical-stage oncology portfolio based on its proprietary ADC platform and PD-1/VEGF bispecific antibodies, together with late-stage autoimmune assets advancing towards commercialisation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- METIS TECHBIO-P (07666.HK): Added as Hang Seng Composite Index Constituent, Effective 7 September
- SUNSHINE OIL (02012.HK): Subsidiary Holds 40% Stake in New Joint Venture to Build 6,000P Computing Power Centre
- CH GENERAL EDU (02175.HK): Target Company Unlikely to Meet 2026 Net Profit Target; Agreement in Principle to Reduce Acquisition Consideration
- PATEO (02889.HK): Acquires 20% Equity of Seagull Kitchen & Bath for RMB 800 Million and Becomes Controlling Shareholder, Constituting a Major Transaction
- XINXIN MINING(03833.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 249.42 million, YoY increase of 248.13%
